Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Tries To Chase Down Pfizer With Phase III Pentavalent Meningococcal Vaccine Data

Executive Summary

Phase III data for a vaccine combining Bexsero and Menveo demonstrated non-inferiority. GSK hopes to file it for approval soon, while Pfizer’s candidate has an October FDA action date.

You may also be interested in...



GSK Set To Compete Against Pfizer In Pentavalent Meningococcal Vaccination, But When?

The company presented data for its MenABCWY vaccine, but it still hasn’t specified the timing for approval. While its launch would lag Pfizer’s, GSK has an advantage in terms of data as well as leadership in the space.

Keeping Track: A Blizzard Of Submissions At The US FDA

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion

GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel